TY - JOUR
T1 - Characteristics of perimenstrual asthma and its relation to asthma severity and control
T2 - Data from the Severe Asthma Research Program
AU - Rao, Chitra K.
AU - Moore, Charity G.
AU - Bleecker, Eugene
AU - Busse, William W.
AU - Calhoun, William
AU - Castro, Mario
AU - Chung, Kian Fan
AU - Erzurum, Serpil C.
AU - Israel, Elliot
AU - Curran-Everett, Douglas
AU - Wenzel, Sally E.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Busse has provided advisory board services to Merck & Co, Inc and consulting services to Amgen Inc; Novartis AG; GlaxoSmithKline plc; MedImmune, LLC; and Genentech, Inc. He also has received royalties from Elsevier BV and National Institutes of health (NIH) university grant monies from the National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute. Dr Calhoun reports grant funding from the NIH and Alcon Laboratories, Inc and consultant income from Genentech, Inc and Merck & Co, Inc. Dr Castro served as consultant or on the advisory board for Genentech, Inc; Innovative Pulmonary Solutions, Inc; MedImmune, LLC; NKT Therapeutics, Inc; and Schering-Plough. He lectured for Asthmatx/Boston Scientific Corporation, AstraZeneca; Boehringer Ingelheim GmbH; Genentech, Inc; GlaxoSmithKline plc; Merck & Co, Inc; and Pfizer, Inc. His university received industry-sponsored grants from Amgen Inc; Asthmatx/Boston Scientific Corporation; Ception Therapeutics, Inc/Cephalon, Inc; Genentech, Inc; GlaxoSmithKline plc; MedImmune, LLC; Merck & Co, Inc; Novartis AG, and sanofi-aventis US LLC. Dr Castro's university received grant monies from the NIH and the American Lung Association, and he has received royalties from Elsevier BV. Dr Chung has received university grant monies from the Wellcome Trust, Medical Research Council, Asthma UK, NIH, and National Environmental Research Council (UK). He has also been remunerated for participating at advisory board meetings with GlaxoSmithKline plc and Gilead and for participating in speaking activities at the invitation of Novartis AG and GlaxoSmithKline plc. Drs Rao, Moore, Bleecker, Erzurum, Israel, Curran-Everett, and Wenzel have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
PY - 2013/4
Y1 - 2013/4
N2 - Background: Although perimenstrual asthma (PMA) has been associated with severe and difficult-to-control asthma, it remains poorly characterized and understood. The objectives of this study were to identify clinical, demographic, and inflammatory factors associated with PMA and to assess the association of PMA with asthma severity and control. Methods: Women with asthma recruited to the National Heart, Lung, and Blood Institute Severe Asthma Research Program who reported PMA symptoms on a screening questionnaire were analyzed in relation to basic demographics, clinical questionnaire data, immunoinflammatory markers, and physiologic parameters. Univariate comparisons between PMA and non-PMA groups were performed. A severity-adjusted model predicting PMA was created. Additional models addressed the role of PMA in asthma control. Results: Self-identified PMA was reported in 17% of the subjects (n = 92) and associated with higher BMI, lower FVC % predicted, and higher gastroesophageal reflux disease rates. Fifty-two percent of the PMA group met criteria for severe asthma compared with 30% of the non-PMA group. In multivariable analyses controlling for severity, aspirin sensitivity and lower FVC % predicted were associated with the presence of PMA. Furthermore, after controlling for severity and confounders, PMA remained associated with more asthma symptoms and urgent health-care utilization. Conclusions: PMA is common in women with severe asthma and associated with poorly controlled disease. Aspirin sensitivity and lower FVC % predicted are associated with PMA after adjusting for multiple factors, suggesting that alterations in prostaglandins may contribute to this phenotype.
AB - Background: Although perimenstrual asthma (PMA) has been associated with severe and difficult-to-control asthma, it remains poorly characterized and understood. The objectives of this study were to identify clinical, demographic, and inflammatory factors associated with PMA and to assess the association of PMA with asthma severity and control. Methods: Women with asthma recruited to the National Heart, Lung, and Blood Institute Severe Asthma Research Program who reported PMA symptoms on a screening questionnaire were analyzed in relation to basic demographics, clinical questionnaire data, immunoinflammatory markers, and physiologic parameters. Univariate comparisons between PMA and non-PMA groups were performed. A severity-adjusted model predicting PMA was created. Additional models addressed the role of PMA in asthma control. Results: Self-identified PMA was reported in 17% of the subjects (n = 92) and associated with higher BMI, lower FVC % predicted, and higher gastroesophageal reflux disease rates. Fifty-two percent of the PMA group met criteria for severe asthma compared with 30% of the non-PMA group. In multivariable analyses controlling for severity, aspirin sensitivity and lower FVC % predicted were associated with the presence of PMA. Furthermore, after controlling for severity and confounders, PMA remained associated with more asthma symptoms and urgent health-care utilization. Conclusions: PMA is common in women with severe asthma and associated with poorly controlled disease. Aspirin sensitivity and lower FVC % predicted are associated with PMA after adjusting for multiple factors, suggesting that alterations in prostaglandins may contribute to this phenotype.
UR - http://www.scopus.com/inward/record.url?scp=84876012788&partnerID=8YFLogxK
U2 - 10.1378/chest.12-0973
DO - 10.1378/chest.12-0973
M3 - Article
C2 - 23632943
AN - SCOPUS:84876012788
SN - 0012-3692
VL - 143
SP - 984
EP - 992
JO - CHEST
JF - CHEST
IS - 4
ER -